Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Stoke Therapeutics (STOK) FCF Margin: 2022-2025

Historic FCF Margin for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -286.85%.

  • Stoke Therapeutics' FCF Margin rose 15692.00% to -286.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.47%, marking a year-over-year increase of 53133.00%. This contributed to the annual value of -238.15% for FY2024, which is 70357.00% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' FCF Margin is -286.85%, which was down 54.97% from -185.11% recorded in Q2 2025.
  • Stoke Therapeutics' 5-year FCF Margin high stood at 1,055.00% for Q1 2022, and its period low was -897.18% during Q2 2023.
  • Its 3-year average for FCF Margin is -407.45%, with a median of -425.10% in 2023.
  • Per our database at Business Quant, Stoke Therapeutics' FCF Margin slumped by 148,010bps in 2023 and then skyrocketed by 66,601bps in 2025.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' FCF Margin stood at -697.12% in 2022, then crashed by 4,799bps to -745.11% in 2023, then spiked by 64,236bps to -102.75% in 2024, then skyrocketed by 15,692bps to -286.85% in 2025.
  • Its FCF Margin stands at -286.85% for Q3 2025, versus -185.11% for Q2 2025 and 83.04% for Q1 2025.